GlassScriptPhysician profile
Aree I Saed
NPI 1588828263
$4,951.02
in general payments reported to CMS, 2019-2025
37 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $680 · 2021: $828 · 2022: $764 · 2023: $698 · 2024: $667 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836 · Long Term Medical Supply Or Device Loan: $87.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.92 |
| Long Term Medical Supply Or Device Loan | $87.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $997.44 | 2019-2025 | Collagenase Santyl, Grafix Pl, Stravix Pl |
| Supreme Orthopedic Systems, LLC | $511.93 | 2020 | |
| Mimedx Group, INC. | $361.20 | 2024-2025 | |
| Integra Lifesciences Corporation | $330.91 | 2019-2025 | Integra, Cytal, Tcc-Ez |
| Organogenesis INC. | $265.69 | 2019-2025 | Apligraf |
| Convatec INC. | $256.84 | 2023-2024 | |
| Boston Scientific Corporation | $250.04 | 2019-2021 | |
| Tactile Systems Technology INC | $207.69 | 2020-2022 | |
| Stryker Corporation | $199.52 | 2021-2022 | |
| Next Science LLC | $194.96 | 2023-2024 | Surgx, Blastx, Xperience |
| Biocomposites INC | $140.37 | 2019-2021 | |
| Abbvie INC. | $137.53 | 2021-2023 | Dalvance, Teflaro |
| Musculoskeletal Transplant Foundation INC. | $128.44 | 2022-2023 | |
| Abbott Laboratories | $110.43 | 2023 | Proclaim |
| Treace Medical Concepts, INC. | $90.11 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $78.27 | 2020-2023 | |
| Paratek Pharmaceuticals, INC. | $72.70 | 2022-2023 | Nuzyra |
| Melinta Therapeutics, LLC | $59.25 | 2019-2023 | Kimyrsa |
| Davol INC. | $56.76 | 2023-2024 | Arista Ah Flexitip |
| Hydrofera LLC | $50.60 | 2024 | Hydrofera Blue |
| Progenacare Global, LLC | $49.74 | 2023 | |
| Hartmann USA, INC. | $48.34 | 2022-2025 | Zetuvit Plus 10x10 P10 |
| Osteomed LLC | $42.04 | 2019 | |
| Misonix INC | $34.32 | 2021 | |
| Wright Medical Technology, INC. | $34.04 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $33.99 | 2021 | |
| Ets Wound Care LLC | $28.44 | 2024 | Mirragen Advanced Wound Matrix |
| Horizon Therapeutics Plc | $25.03 | 2019 | |
| Amgen INC. | $23.45 | 2024 | Krystexxa |
| Kerecis Limited | $21.39 | 2021-2022 | |
| Averitas Pharma INC. | $19.19 | 2024 | Qutenza |
| Sebela Pharmaceuticals INC. | $18.53 | 2022 | |
| Bioventus LLC | $16.51 | 2023 | |
| Novum Pharma, LLC | $16.28 | 2019 | |
| Triad Life Sciences INC. | $14.30 | 2022 | |
| Amniox Medical, INC. | $12.41 | 2019 | |
| Nevro Corp. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aree Saed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.